London, March 24, 2026, 18:30 GMT
- GSK finished the day up 2.07% at 1,977 pence on the London market. Over in New York, its U.S.-listed shares added roughly 1.7%.
- Risvutatug rezetecan picked up orphan-drug status in Japan for small-cell lung cancer on Monday.
- Regulatory filings reveal that Chair Jonathan Symonds and director Gavin Screaton have both picked up shares recently, joining ongoing buybacks.
GSK shares finished Tuesday up 2.07% at 1,977 pence, beating out the FTSE 100’s 0.72% gain. The move came after the British pharma firm announced that Japan had granted orphan-drug status to its investigational lung cancer therapy, risvutatug rezetecan.
This shift comes at a crucial moment: investors want to see GSK deliver on its promise to push new drugs through the pipeline, as Chief Executive Luke Miels races to boost development and line up fresh medicines before patents run out in the HIV segment. “We need to accelerate what we have,” Miels said back in February, outlining a strategy that leans on brisker R&D and targeted acquisitions. Reuters
Japan’s nod comes on the heels of several green lights for GSK. Just last week, the U.S. FDA cleared Lynavoy to treat severe itching tied to primary biliary cholangitis, a chronic liver disorder. Earlier in the month, regulators also expanded the U.S. label for Arexvy—GSK’s RSV vaccine—to include at-risk adults ages 18 to 49. That move squares GSK off with Pfizer and Moderna in the same demographic.
Japan’s orphan-drug designation goes to treatments targeting serious illnesses with fewer than 50,000 patients nationally. GSK says risvutatug rezetecan just picked up the label—its sixth global regulatory nod—based on early data in extensive-stage small-cell lung cancer, or SCLC. The therapy is an antibody-drug conjugate, designed to deliver a cytotoxic payload directly to cancer cells.
This disease moves quickly and is tough to manage. GSK noted that most people with extensive-stage SCLC see their cancer return after first-line treatment, with median overall survival on standard care stuck at around eight months. Amgen’s Imdelltra, though, has already secured full U.S. approval in this setting following platinum-based chemo.
Investors got another cue from a batch of filings. GSK revealed Monday that Chair Jonathan Symonds scooped up 5,000 ordinary shares on March 20, paying an average of 19.5111 pounds each. Director Gavin Screaton picked up 6,335 shares two days earlier, on March 18. The company added that it repurchased 560,000 shares for treasury as part of its ongoing buyback programme.
The stock clawed back some ground Tuesday but still sits 13.37% under its 52-week peak at 2,282 pence set on Feb. 18. GSK’s U.S. shares traded roughly 1.7% higher, at $52.87, during the New York afternoon.
Still, orphan status isn’t the same as a green light—or a payday. GSK pointed out the Japanese move is tied to phase I data. Its global phase III trial for relapsed extensive-stage SCLC kicked off just in August 2025, so clinical and regulatory hurdles remain in play for quite a while.
Brokers haven’t dropped their guard yet. On Tuesday, MarketScreener noted that Emmanuel Papadakis at Deutsche Bank maintained a neutral stance on GSK, sticking with a 1,900-pence target—still under GSK’s London close.
